Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023
C He, X Hu, M Wang, X Yin, M Zhan, Y Li… - Frontiers in …, 2024 - frontiersin.org
Background Mild cognitive impairment is a heterogeneous syndrome. The heterogeneity of
the syndrome and the absence of consensus limited the advancement of MCI. The purpose …
the syndrome and the absence of consensus limited the advancement of MCI. The purpose …
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology
Background Dementia preventive interventions targeting multiple modifiable risk factors are
a promising approach. However, the impact of modifiable risk factors in the presence of beta …
a promising approach. However, the impact of modifiable risk factors in the presence of beta …
Altered brain connectivity in mild cognitive impairment is linked to elevated tau and phosphorylated tau, but not to GAP-43 and Amyloid-β measurements: a resting …
M Sadeghi, A Azargoonjahromi, H Nasiri, A Yaghoobi… - Molecular Brain, 2024 - Springer
Abstract Mild Cognitive Impairment (MCI) is a neurological condition characterized by a
noticeable decline in cognitive abilities that falls between normal aging and dementia. Along …
noticeable decline in cognitive abilities that falls between normal aging and dementia. Along …
[HTML][HTML] Tiaogeng decoction improves mild cognitive impairment in menopausal APP/PS1 mice through the ERs/NF-κ b/AQP1 signaling pathway
X Li, Z Lin, S Chen, S Ni, G Lin, W Wang, J Lin, Q Zhao… - Phytomedicine, 2025 - Elsevier
People with mild cognitive impairment (MCI) carry a considerable risk of developing
dementia. Studies have shown that female sex hormones have long-lasting neuroprotective …
dementia. Studies have shown that female sex hormones have long-lasting neuroprotective …
[HTML][HTML] Evaluating the Efficacy of Levetiracetam on Non-Cognitive Symptoms and Pathology in a Tau Mouse Model
JC Thompson, M Levis Rabi, M Novoa, KR Nash… - Biomedicines, 2024 - mdpi.com
Background/Objectives: Alzheimer's disease (AD) is marked by amyloid-β plaques and
hyperphosphorylated tau neurofibrillary tangles (NFTs), leading to cognitive decline and …
hyperphosphorylated tau neurofibrillary tangles (NFTs), leading to cognitive decline and …
[HTML][HTML] Cerebral perfusion correlates with amyloid deposition in patients with mild cognitive impairment due to Alzheimer's disease
C Wang, D Ji, X Su, F Liu, Y Zhang, Q Lu, L Cai… - The Journal of …, 2025 - Elsevier
Background Changes in cerebral blood flow (CBF) may contribute to the initial stages of the
pathophysiological process in patients with Alzheimer's disease (AD). Hypoperfusion has …
pathophysiological process in patients with Alzheimer's disease (AD). Hypoperfusion has …
[HTML][HTML] Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand …
T Kaewchur, T Thientunyakit, W Chamroonrat… - Diagnostics, 2024 - mdpi.com
Nuclear medicine investigations play a significant role in diagnosing dementia, mainly using
imaging techniques such as positron emission tomography (PET) and single-photon …
imaging techniques such as positron emission tomography (PET) and single-photon …
The noradrenergic system and agitation in Alzheimer's disease
KY Liu - 2024 - discovery.ucl.ac.uk
Aims: The thesis tests aspects of the hypothesis that Alzheimer's disease (AD)-related
neurodegeneration of the noradrenergic locus coeruleus (LC) contributes to agitation …
neurodegeneration of the noradrenergic locus coeruleus (LC) contributes to agitation …
Predicting the Time to Onset of Alzheimer's Disease in Subjects with Mci—A Mathematical Interpretation
T NAKAMURA, B Zhou, M Fukushima - Available at SSRN 5061256 - papers.ssrn.com
Background: The diagnosis framework of Alzheimer's disease (AD) based on elevated PET
Abeta, tau, and plasma ptau217 and ptau231 predict a high risk of AD in people with MCI …
Abeta, tau, and plasma ptau217 and ptau231 predict a high risk of AD in people with MCI …